Samenvatting

Summary of the entire course Preclinical Drug Research (18/20)

Name: Summary of the entire course Preclinical Drug Research (18/20)
SKU: doc_3617585
Rating: 5.00 (1 reviews)
Author: lemmeslodders

1 beoordeling

3 keer verkocht

Instelling
Universiteit Antwerpen (UA)

Summary of the entire course Preclinical Drug Research (18/20): This is a compact summary of the whole course from the subject Preclinical Drug Research (slides, lectures, and all the important information from the insert) & elaboration of all the old exam questions from the course Preclinical Drug...

[Meer zien]

Voorbeeld 4 van de 164 pagina's

Bekijk voorbeeld

Geupload op 13 oktober 2023
Aantal pagina's 164
Geschreven in 2023/2024
Type Samenvatting

preclinical
preclinical drug research
pharmacokinetics
delputte
biopharmaceuticals
vaccines
antibodies
biotechnology
biotechnological products
biomedical sciences

1 beoordeling

Door: bullshit1 • 5 maanden geleden

Volgen

lemmeslodders Lid sinds 4 jaar 246 documenten verkocht

€18,39

Ook beschikbaar in voordeelbundel v.a. €19,99

In winkelwagen

Opslaan

100% tevredenheidsgarantie
Direct beschikbaar na je betaling
Lees online óf als PDF
Geen vaste maandelijkse kosten

Ook beschikbaar in voordeelbundel (1)

Summary of the entire course Preclinical Drug Research (18/20)

€ 78,84 € 19,99

5x verkocht

6 items

1. Samenvatting - Summary of the entire course preclinical drug research (18/20)
2. Samenvatting - Summary of the entire course preclinical drug research (18/20)
3. Samenvatting - Summary of the entire course preclinical drug research (18/20)
4. Samenvatting - Summary of the entire course preclinical drug research (18/20)
5. Samenvatting - Summary of the entire course preclinical drug research (18/20)
6. Samenvatting - Summary of everything that’s important from the insert and of the entire course pre...
Meer zien

Complete summary of Preclinical
Drug Research

geschreven door

jantimmermans

www.stuvia.com

Gedownload door: jitseopdebeeck1 | Wil jij €76 per
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar. maand verdienen?

, Stuvia - Koop en Verkoop de Beste Samenvattingen

Summary
preclinical drug
research
2018

Semester 1 2020-2021

1st Master Biomedical sciences
University of Antwerp

1
Gedownload door: jitseopdebeeck1 | Wil jij €76 per
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar. maand verdienen?

, Stuvia - Koop en Verkoop de Beste Samenvattingen

Table of contents
Inhoud
Table of contents .............................................................................................................................................................................................. 2
Exam information .............................................................................................................................................................................................. 7
1 Introduction to drug R&D and the pharmaceutical industry ................................................................................................................... 8
1.1 Introduction............................................................................................................................................................................... 8
1.2 Some facts and figures ............................................................................................................................................................. 8
1.3 Development costs and revenue cycle...................................................................................................................................... 9
1.4 Timelines of drug development ............................................................................................................................................... 11
1.5 Challenges for the pharmaceutical industry ............................................................................................................................ 12
1.6 Product positioning ................................................................................................................................................................. 13
1.7 Failure rates in drug development ........................................................................................................................................... 13
1.8 Drug targets............................................................................................................................................................................ 14
1.9 Biotech-derived medicines ...................................................................................................................................................... 15
1.10 Major pharmaceutical companies ........................................................................................................................................... 15
2 Drug discovery process ...................................................................................................................................................................... 19
2.1 Therapeutic modalities............................................................................................................................................................ 19
2.1.1 Types of therapeutics .................................................................................................................................................... 19
2.2 Current therapeutics ............................................................................................................................................................... 19
2.2.1 Conventional therapeutic drugs ..................................................................................................................................... 19
2.2.2 Biopharmaceuticals....................................................................................................................................................... 20
2.3 General principles of drug discovery process .......................................................................................................................... 22
2.3.1 Introduction ................................................................................................................................................................... 22
2.3.2 Current trends in drug discovery ................................................................................................................................... 24
2.4 Selection criteria for oral drug candidate (in early discovery phase) ........................................................................................ 24
2.4.1 Chemical characteristics ............................................................................................................................................... 24
2.4.2 Pharmacological ........................................................................................................................................................... 25
2.4.3 Pharmacokinetic ........................................................................................................................................................... 25
2.4.4 toxicological .................................................................................................................................................................. 25
2.5 Choosing the project ............................................................................................................................................................... 25
3 Target identification and validation ..................................................................................................................................................... 27
3.1 Drug target interaction ............................................................................................................................................................ 27
3.2 Strategies for finding new drug targets.................................................................................................................................... 28
3.2.1 Conventional strategies to find new drug targets ........................................................................................................... 28
3.2.2 New strategies for drug target identification .................................................................................................................. 29
3.2.3 New strategies for drug target validation ....................................................................................................................... 30
4 Lead finding and lead optimization (drug screening) ........................................................................................................................... 32
4.1 Introduction............................................................................................................................................................................. 32
4.2 Definitions............................................................................................................................................................................... 33
4.2.1 Hits ............................................................................................................................................................................... 33
4.2.2 Leads ............................................................................................................................................................................ 33
4.3 The drug candidate ................................................................................................................................................................. 34
4.4 Lipinski’s rule .......................................................................................................................................................................... 34
4.5 Hit and lead identification ........................................................................................................................................................ 35

2
Gedownload door: jitseopdebeeck1 | Wil jij €76 per
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar. maand verdienen?

, Stuvia - Koop en Verkoop de Beste Samenvattingen

4.5.1 Random (high throughput screening of compound libraries ........................................................................................... 35
4.5.2 Knowledge-based ......................................................................................................................................................... 35
4.6 Drug screening technologies .................................................................................................................................................. 35
4.6.1 Background .................................................................................................................................................................. 35
4.7 Practical: high throughput methods and set up ....................................................................................................................... 36
4.7.1 Compound logistics....................................................................................................................................................... 36
4.7.2 Assay development....................................................................................................................................................... 36
4.7.3 Automated screening .................................................................................................................................................... 36
4.7.4 Assay validation in high throughput .............................................................................................................................. 36
4.8 Screening assay types............................................................................................................................................................ 37
4.8.1 Cell-free in vitro system................................................................................................................................................. 37
4.8.2 Cell-based in vitro system ............................................................................................................................................. 39
4.9 Lead structure requirements ................................................................................................................................................... 40
4.9.1 Suitable molecular properties ........................................................................................................................................ 40
4.9.2 Favorable pharmacodynamics ...................................................................................................................................... 40
4.9.3 Acceptable pharmacokinetics........................................................................................................................................ 40
4.9.4 Chemical optimization potential..................................................................................................................................... 40
4.9.5 Patentability .................................................................................................................................................................. 40
5 Pharmacokinetics in drug discovery.................................................................................................................................................... 41
5.1 Introduction............................................................................................................................................................................. 41
5.2 Basics of pharmacokinetics .................................................................................................................................................... 42
5.2.1 Absorption .................................................................................................................................................................... 42
5.2.2 Distribution.................................................................................................................................................................... 43
5.2.3 Metabolisation............................................................................................................................................................... 44
5.2.4 Elimination .................................................................................................................................................................... 46
5.2.5 Steady-state.................................................................................................................................................................. 47
5.2.6 One-compartment model .............................................................................................................................................. 47
5.2.7 Two-compartment model .............................................................................................................................................. 47
5.3 Drug transporters.................................................................................................................................................................... 48
5.4 Drug properties and PK characteristics ................................................................................................................................... 49
5.5 Determining the plasma concentration of your drug ................................................................................................................ 50
5.6 In silico prediction of DMPK properties ................................................................................................................................... 51
5.7 Physicochemical properties .................................................................................................................................................... 52
5.7.1 Charge state ................................................................................................................................................................. 52
5.7.2 Lipophilicity ................................................................................................................................................................... 52
5.7.3 Aqueous solubility ......................................................................................................................................................... 53
5.8 In vivo pharmacokinetics ........................................................................................................................................................ 53
5.8.1 Exploratory pharmacokinetics ....................................................................................................................................... 53
5.8.2 Whole body autoradiography ........................................................................................................................................ 53
6 Pharmacology .................................................................................................................................................................................... 54
6.1 Introduction............................................................................................................................................................................. 54
6.2 Screening for selectivity (in vitro) ............................................................................................................................................ 56
6.2.1 Saturation assay ........................................................................................................................................................... 56
6.2.2 Displacement assay ...................................................................................................................................................... 57
6.3 Pharmacological profiling ........................................................................................................................................................ 57
6.3.1 In vitro profiling on isolated tissues................................................................................................................................ 57

3
Gedownload door: jitseopdebeeck1 | Wil jij €76 per
Dit document is auteursrechtelijk beschermd, het verspreiden van dit document is strafbaar. maand verdienen?

Dit zijn jouw voordelen als je samenvattingen koopt bij Stuvia:

Bewezen kwaliteit door reviews

Studenten hebben al meer dan 850.000 samenvattingen beoordeeld. Zo weet jij zeker dat je de beste keuze maakt!

In een paar klikken geregeld

Geen gedoe — betaal gewoon eenmalig met iDeal, Bancontact of creditcard en je bent klaar. Geen abonnement nodig.

Focus op de essentie

Studenten maken samenvattingen voor studenten. Dat betekent: actuele inhoud waar jij écht wat aan hebt. Geen overbodige details!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.